Otros idiomas Castle Biosciences, Inc.

Acciones

CSTL

US14843C1053

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
20,34 ^USD	+4,25 %		+5,33 %	-5,75 %

08/04	Un iniciado de Castle Biosciences vendió acciones por valor de 441.853 dólares, según un reciente registro de la SEC	MT
04/04	Castle Biosciences, Inc. anuncia que compartirá nuevos datos en el 20º Congreso de la Asociación Europea de Dermato-Oncología	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024	11/04
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations	10/04
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year	10/04
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing	08/04
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer	04/04
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress	04/04
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Castle Biosciences Announces Updates to its Board of Directors	27/03
Castle Biosciences, Inc. Announces Board Changes	27/03
Castle Biosciences, Inc. - Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years	25/03
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year	25/03
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB	22/03
Castle Biosciences - Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy	20/03
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy	19/03
Castle Biosciences, Inc. Announces the Publication of an Expert Consensus Article in the Journal of Clinical and Aesthetic Dermatology	19/03
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older	15/03
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences and MedTech Investor Forum	13/03
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum	12/03
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting	08/03
Castle Biosciences - In Novel Cohort, New Data Confirms DecisionDx-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups	08/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Castle Biosciences, Inc.

Acciones

CSTL

US14843C1053

Otros idiomas

Filtros